BiotechTube

pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mg

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cushing's Disease

Conditions

Cushing's Disease

Trial Timeline

Nov 4, 2011 → Dec 21, 2016

NCT ID
NCT01374906

About pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mg

pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mg is a phase 3 stage product being developed by Novartis for Cushing's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01374906. Target conditions include Cushing's Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01374906Phase 3Completed

Competing Products

18 competing products in Cushing's Disease

See all competitors
ProductCompanyStageHype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisoloneAstraZenecaPhase 2
52
Pasireotide sub-cutaneousNovartisPhase 3
77
osilodrostat + osilodrostat PlaceboNovartisPhase 3
77
OsilodrostatNovartisPhase 2
52
PasireotideNovartisPhase 3
77
Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
85
SOM230 s.c.NovartisPhase 2
52
Lu AG13909LundbeckPhase 2
49
OsilodrostatRecordatiPre-clinical
20
Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved
82
osilodrostatRecordatiPhase 2
49
OsilodrostatRecordatiPre-clinical
20
mifepristoneCorcept TherapeuticsPhase 3
72
CORT125134Corcept TherapeuticsPhase 2
47
Cushing's syndrome confirmationCorcept TherapeuticsPre-clinical
18
MifepristoneCorcept TherapeuticsPhase 3
72
mifepristoneCorcept TherapeuticsPhase 3
72
mifepristoneCorcept TherapeuticsPhase 3
72

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85